Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose thoracic radiotherapy followed by adebrelimab plus chemotherapy and sequential adebrelimab maintenance in extensive-stage small cell lung cancer
ChiCTR2600134711Phase 2Recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Jiangmen Central Hospital. Primary endpoint: Progression-Free Survival. Started Jul 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600134711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134711.